Literature DB >> 31159619

The role of metastasectomy in advanced renal cell carcinoma.

Giulia Apollonio1, Alessandra Raimondi1, Elena Verzoni1, Melanie Claps1, Pierangela Sepe1, Filippo Pagani1, Raffaele Ratta1, Francesco Montorsi2, Filippo Guglielmo Maria De Braud1, Giuseppe Procopio1.   

Abstract

Introduction: So far, clinical experiences have proved metastasectomy as the only approach in the setting of metastatic renal cell carcinoma that may achieve the 'no evidence of disease' status, with an associated improvement in survival. Areas covered: This review aims to summarize the body of knowledge on therapeutic approaches to mRCC, with a specific insight on the role of metastasectomy and on which underlying factors could be good predictors to select patients who may benefit from surgery. In detail, we managed to identify as potential selection criteria: the number of lesions and their site, the DFI, patients' performance status and, most of all, the completeness of resection. Expert opinion: The definition of the optimal treatment strategy of mRCC patients is still an unmet clinical need. The decision-making process about treatment strategy should consider specific tumor's and patient's characteristics, as well as the integration of the available therapeutic approaches with the aim to reach the best clinical outcome. We consider multidisciplinary management mandatory in order to tailor the treatment approach according to the patient and disease features. The experience of clinicians may be considered crucial in order to select the best candidates for a multimodal approach.

Entities:  

Keywords:  Metastasectomy; immunotherapy; renal cell carcinoma; surgical approach; targeted therapies

Mesh:

Year:  2019        PMID: 31159619     DOI: 10.1080/14737140.2019.1625772

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  1 in total

Review 1.  Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG).

Authors:  Andrey Soares; Fernando Sabino Marques Monteiro; Fernando Cotait Maluf; Diogo Assed Bastos; Denis Leonardo Jardim; André Deeke Sasse; Adriano Gonçalves E Silva; André P Fay; Diogo Augusto Rodrigues da Rosa; Evanius Wierman; Fabio Kater; Fabio A Schutz; Fernando Nunes Galvão de Oliveira; Igor Alexandre Protzner Morbeck; José Augusto Rinck; Karine Martins da Trindade; Manuel Caitano Maia; Vinicius Carrera Souza; Deusdedit Cortez Vieira da Silva Neto; Felipe de Almeida E Paula; Fernando Korkes; Gustavo Franco Carvalhal; Lucas Nogueira; Roni de Carvalho Fernandes; Rodolfo Borges Dos Reis; Wagner Eduardo Matheus; Wilson Francisco Schreiner Busato; Walter Henriques da Costa; Stênio de Cássio Zequi
Journal:  J Cancer Res Clin Oncol       Date:  2020-05-14       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.